Positron Emission Tomography (PET) in Oncology

Dear Colleagues,

Positron emission tomography (PET) has been called “the fastest growing medical technology ever”. Regardless of whether this is absolutely true, there is no doubt that PET has dramatically changed the handling of many cancer patients.
PET has in different cancer forms proved to be excellent for diagnosing, staging and treatment monitoring. FDG-PET has strong prognostic value and may be used for tailoring therapy including external radiation.
Accordingly, decades of evaluation and research of mainly FDG-PET has established this as a powerful tool in cancer patients. However, this may only be the beginning of the PET era since the concept of molecular imaging with use of different PET tracers for tissue characterization in cancer may very well be what is needed to make the paradigm of tailored therapy come true.
This special issue invites all types of submission on use of PET in cancer. Both experimental, preclinical and clinical papers are welcome.

Dr. Annika Loft
Collection Editor

Manuscript Submission Information

Manuscripts for the topical collection can be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on this website. The topical collection considers regular research articles, short communications and review articles. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page.

Please visit the Instructions for Authors page before submitting a manuscript. The article processing charge (APC) for publication in this open access journal is 2600 CHF (Swiss francs). English correction and/or formatting fees will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections. For further details see here.